Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Questions on post from you ED20332.
1) Is this a national news wire site?
2) Who are 'They'? as in person, company, etc. in 'They just put out a new press release(here)...'
3) Is overseas being included? 'The company claims they have 21 employees. Yet somehow, they managed to burn through $3.1 million dollars in a quarter...'
4) Comment more then question. We all have been aware of this from the filing and reason for it. 'Additionally, from the 10-Q, we have more dilution. "During the three months ended March 31, 2010, investors converted 636,860 shares of Series B Preferred Stock into 63,686,000 shares of common stock."'
5) Who is Patrick?
Thanks in advance.
I am surprised we closed down.
With over a 2 to 1 Buy to Sell volume ratio, I am really surprised we closed lower. I surely thought with the change in buying going up, and it being a while since we saw this ratio in volume support, that we were going further upwards in price.
Barber, I see what you are saying, and I can see how others can look at it and affect the stock. Thanks!
I would be surprised if we do not close at least at .133 or higher. I could even see .15 being possible with the buying volume from today.
Billy, I am trying to get a feel for one year dollar earnings and not an earning over 5 years, as if you do then I think you have to divide the $ by the number of years. At least in how I look at it.
Let's say the bottom line profit is $2B over 5 years. That would be about $400M each year averaged. I would use the $400M and then divide if by the number of outstanding shares.
Right now we are sitting at 600M shares. I could see that growing over time depending on what is said here on the partnership, and based upon the growing number of OS this year. Just trying to look at both sides and not be one sided in thought, but still on the positive side.
Just my way of looking at it, and not maybe how everyone else looks at it. To me future events could change quickly, so I do not like to look that far out. Maybe two years, but again how I look at it.
I think .50 is easily obtainable so long as they come out next week with the news we have been waiting for and annoucing Covidien as one of the partners. I think we are maybe looking or two in who Positron has been wording things since MarketSite and maybe a little before that.
Barber, are you facturing in the yearly expenses, development cost, etc. and looking at this in a yearly setting to come up with your numbers?
Depending on the partnership deal, I could see anywhere from $0.50 to $2.00 or more depending on sales also.
Nice to see the strong buying continue...eom
The best thing to do is Squelch TS and any others that you do not wish to see postings on. That is why this site has the feature to help you ignore those that cause problems.
This site shows a whole lot of buying going on compared to selling.
Hopefully this will jump high and run today or next week as we have been waiting for. One way or another we will know by next Friday, assuming we can count on Rooney on his two weeks that he stated last Friday.
Let’s hope the momentum can continue today and we can close at .13 or higher which should help propel us more into next week waiting the pending news.
Fastmandoo, is that news an update from earlier?
I have not looked at it since the posting at 1:00 today.
Here is the link to the original posting.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51411488
I guessed Garza sold his shares as the price was falling in early May. I would be surprised if he held on to them.
Here is the link, Also the full article is listed here. It was cut off I noticed in Billy's post.
Billy included the link in his posting at the bottem. I usually like to put mine towards the top so it is easily seen.
http://biomedreports.com/articles/most-popular/44674-positron-seeing-substantial-accumulation-may-pierce-resistance-levels.html
===================================================================================
Positron seeing substantial accumulation. May pierce resistance levels. PDF | Print | E-mail
Written by M.E.Garza
Thursday, 17 June 2010 14:32
Positron Corporation (OTCBB:POSC), a leader in molecular imaging and solutions specializing in the field of Nuclear Cardiology has just released a report over the news wires highlighting some of the company's key points and developments.
The stock has been seeing quite a bit of accumulation since shares broke the $.10 support level a few days ago and Thursday, shares closed up 11.6% at $.125. We believe the stock will climb higher pending announcements and long awaited official revelation of a key relationship or two with big-cap firms in the biotech imaging space. Those relationships and developments, as they are announced, may signal what investors have been waiting for: the validation and start of next level of commercialization and deployment activities surrounding the company's Molecular Imaging Devices and Radiopharmaceutical Products.
Here is a marked up technical analysis chart of the company:
Here is a synopsis of some of the key points which were announced today by the company:
Positron’s core focus is to leverage their unique technologies and competencies to offer an industry unique total customer solution which includes low cost molecular imaging devices and service, disease specific software, radiopharmaceutical distribution delivery systems, and imaging agents for Nuclear Cardiology. Positron's strategy is to utilize all of its innovative equipment to maximize market share within the molecular imaging market.
Positron’s molecular imaging device segment includes the Attrius™, a Positron Emission Tomography (PET) imaging device that is the only cardiac optimized dedicated PET device in the world.
Positron’s Attrius™ PET scanner, with its robust software package, will help physicians provide a more accurate diagnosis for patients, the potential to reduce unnecessary downstream procedures and allow for higher reimbursement compared to SPECT. Positron also offers a Single Photon Emission Computed Tomography (SPECT) camera, the Pulse™, is one of the leading SPECT imaging devices in the industry with over 150 units sold.
Positron Corp
0.12 +0.01 (+11.61%)
Quotes delayed at least 20 mins.Positron’s radiopharmaceutical segment includes the Nuclear Pharm-Assist® line of equipment, the world’s first robotic system for the distribution of radiopharmaceutical agents for PET and SPECT imaging devices. The Nuclear Pharm-Assist® automates the preparation and dispensing of radiopharmaceuticals and acts as a “virtual pharmacy” located on site at the nuclear pharmacy or physician’s office to dispense the radiopharmaceutical as a patient specific dose. The Nuclear Pharm-Assist® makes the distribution of the radiopharmaceutical economical, efficient and regulatory compliant.
The market at the present time is 7,000+ cardiac imaging opportunities that are all ideal candidates for the evolution of PET imaging and the direct distribution of radiopharmaceuticals.
Positron estimates the market for dedicated cardiac PET scanners in the United States to be above $3 billion in device sales over the next 5 years. According to Bio-Tech Systems, a research firm that covers the diagnostic imaging market, nuclear cardiology radiopharmaceutical sales of $1.29 billion in 2007 will increase to $2.10 billion by 2014. In a study conducted by Frost & Sullivan, the medical imaging consumables market is expected to grow at a compound annual rate of 14 percent, driven by an aging baby boomer population & increased life expectancy this rise is increasing more than twice as fast as the total population.
KEY POINTS & DEVELOPMENTS
PET IMAGING DEVICES
•Positron’s Attrius™ is the only FDA approved standalone dedicated cardiac PET scanner on the market optimized for cardiology. All major PET manufacturers have discontinued manufacturing of PET only systems, offering only PET/CT instead. The addition of an expensive CT provides certain advantages for oncology imaging applications however is not necessary for cardiac imaging procedures. PET/CT has also been shown to have higher radiation exposure levels to patients compared to dedicated PET. Positron intends to fill the market niche with its Attrius™ Cardiac PET.
•The Attrius™ includes a robust, cardiac specific, imaging software package designed to ensure effortless interpretation for today’s most challenging clinical cases for nuclear cardiologists who value high quality PET imagery at an affordable price. The system is designed to provide concurrent acquisition, reconstruction, image processing and display, as well as other functions such as data archiving, without interference.
•Positron’s Attrius™ named “Most Innovative Medical Device of 2010 Award” by the industry leading research firm, Frost and Sullivan.
•A twofold increase in reimbursement of cardiac PET applications by CMS in the last 3 years, with a 25% increase in 2010 alone (while SPECT cardiac imaging reimbursement has been decreased by 20%), which has greatly increased interest in cardiac PET applications. These dramatic changes further validates that PET is the future of nuclear cardiology and that there is an industry wide urgency in the evolution to PET from SPECT.
•CMS (Medicare) has approved PET as a first-line cardiac diagnostic test. The medical imaging industry has regarded PET as the best imaging modality;
•With recent increased reimbursement and challenging medical budgets, it further validates PET as the most efficient, economical and provides the best medicine choice for physicians. PET is the next SPECT which currently is 99% of the cardiac imaging market. As PET replaces a large percentage of SPECT systems, this would represent a total cardiac PET device market of approximately $3 billion dollars.
PHARMACEUTICALS
•Positron’s revolutionary “virtual pharmacy” solutions, Nuclear Pharm-Assist® allows placing pharmaceutical dose delivery systems into nuclear pharmacy’s and/or the physician’s offices and provides unprecedented “Unit Dose” flexibility to imaging providers at the touch of a button, 24/7. The systems meets the requirements of the United States Pharmacopeia Chapter 797 compounding regulations as a compounding aseptic containment isolator (CACI) and provides the ISO Class 5 environment necessary for USP-797 compliance as well as automating the basic radiopharmaceutical compounding procedures. Most Nuclear medicine facilities and nuclear pharmacies are underprepared and have to make considerable investments to meet requirements of USP-797 which are in force since June 2008. Nuclear Pharm-Assist® provides Automation, Shielding, Compliance, Patient management, Costs & Margins.
•Positron has an agreement with an industry leading partner for the development and distribution of cardiac radiopharmaceuticals. This partnership represents thousands of potential customers throughout the US and world. Each distributed Nuclear Pharm-Assist® system represents approximately $250,000 in annual sales. This pending rollout will be the beginning of Positron being a leader in radiopharmaceutical distribution.
•Radiopharmaceuticals, Sestimibi and Rubidium, are now available as a generic pharmaceutical and are set to become commercially available with a number of pharma companies. Lower cost and increased suppliers will help grow our segment of the industry. Positron is working with the largest companies in this field.
•A number of the largest radiopharmaceutical companies are developing single dose cardiac PET imaging agents. This fact alone further validates that PET is the most valuable first line cardiac imaging modality. New cardiac PET specific radiopharmaceuticals will further increase the demand for Positron’s Attrius™ Cardiac PET system, the only new PET only device available today. Positron patient studies demonstrate that the Attrius™ PET scanner meets the performance requirements for all PET myocardial perfusion imaging tracers.
•Positron has a number of patents and patents pending. Most recently has received a patent on its Tech-Assist™, FDG injection shielding device.
•Molybdenum (SPECT drug) shortages have increased the value if not necessity of its model of drug distribution. This drug shortage awakens the industry to the rationale and relevance of the Positron Nuclear Pharm-Assist® line.
Positron will explore additional strategic interests to the Company that advance PET imaging systems and radiopharmaceutical distribution. Positron will continue to evaluate all organic and strategic partnership opportunities and is prepared to engage in more robust business development opportunities that meet its objectives as being the leader in nuclear cardiology. These opportunities could be in a variety of areas, such as partnerships with cardiologist practices, radiopharmaceutical distribution, radiopharmaceutical manufacturing and partnerships with companies that serve the molecular imaging industry. As Positron executes its core focus and strategic interest areas, additional areas may be pursued.
Disclosure: No positions
Seems he is back again...eom
Rick, I agree with you on official release of partnership news.
But I will say I am extremely happy to see both company news releases come out and speaking basically the same thing about one another in what they are doing. Helps me more in feeling good about the news release last month in them saying the partner was actuallly Covidien in their findings. COV is also on the rise that I am seeing at this time.
I would not be surprised if we hit .20 again.
Just to add another two cents on POSC,
From working in a $$B company, winning awards like Frost & Sullivan carries alot of weight when looked at by other partners and clients. It can bring a lot of attention and bring in more contracts than one may think right off.
I think COV and POSC are saying it together in their releases.
From Ricks post http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51406662
Bayou Man, That was originally on 5/21, now_updated.
I see they are re-releasing news again from 5/21, just like I was showing yesterday on another news release about them.
There are probably a few updates as I have not compared todays' to May 21st release.
=========================================================================
http://www.mmdnewswire.com/imagin-molecular-corporation-8551.html
IMAGIN MOLECULAR CORPORATION ACQUIRES AN INVESTMENT POSITION IN POSITRON CORPORATION CURRENTLY VALUED AT $35 MILLION
Chicago, IL (MMD Newswire) May 21, 2010 -- The Board and Shareholders of Imagin Molecular Corporation ("IMGM") have approved certain transactions wherein IMGM completed the acquisition of 3,100,000 Class B Preferred Shares of Positron Corporation which shares are convertible on a one for 100 basis into Positron common shares and therefore currently have a value marked to the current market price for Positron Corporation common shares of in excess of $35 million assuming conversion into commons stock. It is IMGM's current intention to hold the Positron Class B Preferred shares for investment purposes. The consideration for the purchase of the Positron investment position is the issuance of 310,000,000 common shares of IMGM to IMAGIN Diagnostic Centres, Inc. (IDC) a private Canadian company that is in the PET scanning business in Canada and a historical owner 3,100,000 Class B preferred strategic block equity position. IMGM simultaneously will announce its intent to build Cardiac Disease Reversal and Prevention Clinics across Canada and, after initial success, across the USA and globally. The new subsidiary will be named "Positron Cardiac CARE Clinics".
Currently IMGM will hold almost one Positron common share equivalent for each IMGM common share outstanding when the current investment of POSC shares is added to a stock position of 76,235,800 POSC common shares held historically by IMGM. IMGM will own assuming conversion to POSC common stock 386,235,800 Positron common share equivalents. IMGM upon completion of this transaction will have 405,000,000 common shares outstanding with no significant debt or preferred stock outstanding.
About Imagin Molecular Corporation:
Imagin Molecular Corporation (IMGM) is a company dedicated to socially responsible issues. IMGM main areas of interest are focused on medical and environmental. IMGM through its subsidiary Positron Cardiac CARE Clinics ("PCCC") is planning to open Cardiac Disease Reversal Clinics across Canada and after initial success across the USA and globally.
IMGM through a newly to-be-formed 51% owned subsidiary The Planet Green Bottle Corporation has developed and is introducing globally through a subsidiary, the world's first and only oxo-biodegradable PET (polyethylene terephthalate) plastic bottle. The Planet Green oxo-biodegradable technology was developed by Wells Plastics Ltd of the UK and is proprietary with patent pending trademarked by Wells as Reverte.
Imagin Molecular Corporation strategy and focus in its medical segment is dedicated to capitalizing on opportunities in positron emission tomography (PET) directed toward the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. IMAGIN Molecular Corporation has a large strategic equity block position in Positron Corporation. The Positron technology is considered to be the gold standard for cardiac disease diagnosis.
About Planet Green Bottle Corporation
Planet Green Bottle Corporation ("PGBC") initiated with Wells Plastics Ltd. of the UK, the development of a masterbatch additive which causes a PET plastic bottle to become oxo-biodegradable in the environment. The Planet Green concept is to promote its "The PLANET BOTTLE" logo as a brand enhancer wherein the consumer will search for "The PLANET BOTTLE" logo on a brand owner's label as a sign that the plastic bottles and packaging are eco-friendly and will oxo-biodegrade over 10-20 years as opposed to perhaps over 1,000 years for non-treated PET plastic. Planet Green markets its product to brand owners globally. Planet Green is also working with governmental agencies around the world in order to influence legislation mandating that all plastics be treated with oxo-biodegradable additives as a step toward curtailing the pollution of the Planet with Plastic. IMGM acquired the proprietary position and intellectual property of PGBC of Canada in exchange for giving up a 49% interest in its corporate venture to be also called PGBC, a Delaware-incorporated subsidiary.
Contact:
Patrick Rooney
Director of Corporate Development
prooney@rogers.blackberry.net
###
74theroad, I think if you look at what was posted earlier about the Coviden news, and then look at the news today for Positron, you will be able to piece together the parts that are relavent between the two. To me it shows a great sign before the actual news on X and Y are together. So far I think this has been one of the best things they have come out with in a while.
Bayou Man, I do as well otherwise I would not have invested in 220k shares of this company.
Though I have not been liking the idea of how they do or do not release news, or maybe I should say how I wish they would keep their investors up-to-date on what is happening with the timeline. I think we would not have dropped so much if they just came out and said it will be a little longer. Just saying that I think would have kept some investors in and we would not have taken a hard hit (at least in my opinion). I could see it dropping but not exactly as much as it did if they kept the market and investors updated.
Bayou Man, thank you for the news post.
I skimmed over it right off and I like that Positron put out for the market to see, as well as investors existsing and yet to come. I can see this bringing in more investors to the company.
I like the idea of getting a large chunk of thast $3 Billion need out there. I think it helps when the government is even pushing the PET, as well as getting them for their medical centers.
And as I think of it, this seems to work well with Coviden's release. It may be very true the article before about Coviden being the real partner with Positon. Especially bases on Positron's new release and Coviden's new release having in common.
The way this looks in Level II to me, is that it could drop like a rock or fly high if the conditions were right.
I am seeing more MM resistance on the upside then I do in seeing a drop in price.
It will take going through 3 MMs to fall down to .09.
It will take going through 4 MMs to rise up to .121.
Things can change quickly upwards, such as on rumor or release of new good news confirming sales or partnership.
snwbrd, the email addy and phone number is posted on Positron's website. www.positron.com is their main page. you can look under the investor tab for more information
JJ, go to your deleted-post-section and repost it.
When someone from this site deletes your messages, you can go in and still see them for 7 days I believe under Settings and then click on My Removed Posts
Interesting another POSC message deleted. Deleted right after themood11 responded to the message.
It makes me wonder why anyone would delete a message asking when something started to occur with them? As you may remember I answered with "It goes back to at least April."
snwbrd, I agree and have been saying it as well. If he is reading these boards, then he surely is aware.
Pricing dropping here at end.
It goes back to at least April.
I think if we are going to see this hold up and not run down, then it has to be held by the MMs or some large investor(s).
If we close lower today, and I am still expecting no news from POSC or Cov, then we will continue to slide downwards.
What opportunity can be larger than $25B NYSE-Company? Though still waiting to have it validated from their news release.
Let's hope that someone will help push this over .12+ and to .15+ by end of week. I hate to see that trend continue to keep dropping. We really need to see a nice rocket boost here. We are well low from where we should be.
Positron contact information as best I have it.
http://www.positron.com/investors.html
Positron Corporation
7715 Loma Ct., Suite A
Fishers, IN 46038
Toll Free: 866.613.7587
Phone: 317.576.0183
Fax: 317.576.0358
sales@positron.com
That may be hard to answer, as it may depend on your definition of "investors". I consider myself an investor holding 220k shares.
ADVFN Support Team Toll Free: 1-888-99-ADVFN
Hopefully that one sticks this time around.
Posted this morning. I thought I saw this news release (now shown in 3rd part) posted here yesterday, but when I look now I do not see it. Maybe it was on Yahoo, not sure any more, or the site here deleted it thinking it was not relavent.
======================================================================
This was taken from Positron's 8-K on May 11, 2010. Wondering how any of this may be affected or affects the partnership.
Affiliated entities of Positron include companies with common significant shareholders, joint venture companies, joint venture partners and companies with common management or control.
...Imagin Diagnostic Centres, Inc. (“IMAGIN”)
...Quantum Molecular Pharmaceuticals, Inc. (“QMP”)
...Imagin Molecular Corporation (“IMGM”)
...Solaris Opportunity Fund (“Solaris”)
...Neusoft Medical Systems Co. (“NMS”)
...Neusoft Positron Medical Systems Co., Ltd. (“NPMS”)
...Positron Acquisition Corporation (“PAC”)
...Imagin Nuclear Partners (“INP”)
...Note: PAC and INP are wholly-owned subsidiaries of IMGM.
======================================================================
Just more miscellaneous information taken from the 8-K on May 11, 2010.
Positron has the right management with the necessary expertise to meet our objectives. Positron's currently working with a number of strategic alliances that mutually benefit all parties in our expanding businesses.
Positron has an agreement with an industry-leading strategic partner. Positron has agreed with this partner that due to a recent expansion of the relationship and competitive advantages that it is in the best interest of all parties not to disclose any further details at this time. We'll do so in the very near future.
Based on market research and unique positioning in the marketplace, Positron’s targeted revenue projections are approximately $200 million over the next three years and an excess of $1 billion in the next five years. These sales numbers reflect Positron's PET devices and radiopharmaceutical sales and includes accelerated growth that will come from strategic partners.
======================================================================
The news was out first back on 5/21, and I am wondering why they just released the story again? The timing just seems all to odd to me - good or bad, I have no thoughts about it yet.
http://www.forbes.com/feeds/businesswire/2010/06/15/businesswire141113044.html
Press Release
Imagin Molecular Corporation to Change Its Name to the Planet Bottle Corporation
06.15.10, 09:44 AM EDT
BusinessWire - The shareholders of Imagin Molecular Corporation (IMGM) by consent of over 51% of the shareholders have approved a name change of the company to "The Planet Bottle Corporation" (PBC). The new name was chosen because it is expected that the fastest growing segments of the newly revitalized company are environmental projects especially the oxo-biodegradable PET plastic bottle of The Planet Green Bottle Corporation (PGBC). PGBC announced separately an exclusive agreement with Wells Plastics Ltd. of the UK (www.wellsplastics.com) wherein PGBC has introduced a proprietary, patent pending masterbatch additive which will cause the ordinary PET (polyethylene terephthalate) plastic bottle to oxo-biodegrade in 10 to 20 years versus estimates of up to 1,000 years for untreated, non-degradable PET plastic bottle. PGBC, a 51% owned subsidiary to the Planet Bottle Corporation received the registered trademark "The Planet Bottle".
Patrick J. Rooney, Director of Corporate Development for PGBC stated, "The Planet Bottle Corporation is in the business of developing and exploiting certain proprietary technologies which, if successful, could have a profound effect on the production and distribution of the multi-billions of PET (polyethylene terephthalate) plastic bottles that are discarded annually. Only 27% of plastic bottles are recycled with 73% going elsewhere. Planet Bottle has combined two concepts and created a singular solution unique to only Planet Bottle. R-PET describes PET plastic recycled and converted to many non-bottle products, such as t-shirts and carpets as well as recycled bottle to bottle production of a new PET plastic bottle. Until only recently R-PET for bottle to bottle recycling was too scarce and too expensive to be part of a solution. Planet Bottle has incorporated its proprietary REVERTE additive into the production process of R-PET to create the world's first "oxo-biodegradable R-PET plastic bottle". It's easy to sell a R-PET solution, after all COKE, Pepsi and Nestle have all endorsed the R-PET solution. REVERTE merely adds an "insurance policy" to the bottle to deal with the 73% of plastic bottles that are not recycled globally. Our plastic bottles will oxo-biodegrade in microbial environments. Microbes exist in almost all of the environments where bottles are discarded.
Yahoo! BuzzPlanet Bottle continues to introduce brand owners of beverage companies to its proprietary additive, Reverte(TM), as developed by Wells Plastics of the UK. The early adopters are incorporating Reverte in order to facilitate accelerated degradation of plastic. A new concept is being introduced by brand owners to display the Planet Bottle logo which sends the message in the bottle which denotes "This bottle is made from recycled plastic bottles and we recommend that you recycle it again. If the bottle gets inadvertently diverted to landfill or a ditch, it will oxo-biodegrade. The Planet Bottle believes it has an important solution to save the planet from plastic bottle pollution".
About Imagin Molecular Corporation:
Imagin Molecular Corporation (IMGM) is a company dedicated to socially responsible issues. IMGM main areas of interest are focused on medical and environmental. IMGM through its subsidiary Positron Cardiac CARE Clinics ("PCCC") is planning to open Cardiac Disease Reversal Clinics across Canada and after initial success across the USA and globally.
IMGM through a newly to-be-formed 51% owned subsidiary The Planet Green Bottle Corporation has developed and is introducing globally through a subsidiary, the world's first and only oxo-biodegradable PET (polyethylene terephthalate) plastic bottle. The Planet Green oxo-biodegradable technology was developed by Wells Plastics Ltd of the UK and is proprietary with patent pending trademarked by Wells as Reverte.
Imagin Molecular Corporation strategy and focus in its medical segment is dedicated to capitalizing on opportunities in positron emission tomography (PET) directed toward the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. IMAGIN Molecular Corporation has a large strategic equity block position in Positron Corporation. The Positron technology is considered to be the gold standard for cardiac disease diagnosis.
About Planet Green Bottle Corporation
Planet Green Bottle Corporation ("PGBC") initiated with Wells Plastics Ltd. of the UK, the development of a masterbatch additive which causes a PET plastic bottle to become oxo-biodegradable in the environment. The Planet Green concept is to promote its "The PLANET BOTTLE" logo as a brand enhancer wherein the consumer will search for "The PLANET BOTTLE" logo on a brand owner's label as a sign that the plastic bottles and packaging are eco-friendly and will oxo-biodegrade over 10-20 years as opposed to perhaps over 1,000 years for non-treated PET plastic. Planet Green markets its product to brand owners globally. Planet Green is also working with governmental agencies around the world in order to influence legislation mandating that all plastics be treated with oxo-biodegradable additives as a step toward curtailing the pollution of the Planet with Plastic. IMGM acquired the proprietary position and intellectual property of PGBC of Canada in exchange for giving up a 49% interest in its corporate venture to be also called PGBC, a Delaware-incorporated subsidiary.
SOURCE: The Planet Bottle Corporation
For The Planet Bottle Corporation Patrick J. Rooney Director of Corporate Development 416 941-9955
They just deleted my Positon Corp post from this morning.
Why would this site delete important informaiton about Positron Corp on here? What are they wanting to hide?
See my next post.